VYGR - Voyager Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Voyager Therapeutics Inc (VYGR). It includes detailed financial metrics such as market capitalization, income, sales, P/E ratios, employee count, and stock performance data. The report also highlights insider and institutional ownership, analyst recommendations, and key valuation ratios.
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
This article provides the enterprise value to revenue forward for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It confirms that the financial data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to be a financial data point from TradingView.
Price to sales forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
The article focuses on the "Price to sales forward" metric for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It serves as a brief financial data point for the company, indicating a specific period, value, and change percentage for this metric. The content itself seems to be a snapshot from a financial analysis platform like TradingView.
Price to book forward of Voyager Therapeutics, Inc. – FWB:VT6
This article provides the "Price to book forward" financial metric for Voyager Therapeutics, Inc., traded on the Frankfurt Stock Exchange under the ticker FWB:VT6. It indicates that the period value and changes are available, sourced from FactSet Research Systems Inc. and ICE Data Services.
Price to sales forward of Voyager Therapeutics, Inc. – FWB:VT6
This article displays the "Price to sales forward" metric for Voyager Therapeutics, Inc. (FWB:VT6). It includes a table showing the period, value, change, and percentage change for this financial metric. The content itself provides financial data within the TradingView platform.
Voyager’s Alzheimer’s gene therapy gets a late-breaking AAIC poster
Voyager Therapeutics will present a late-breaking poster on its investigational gene therapy, VY1706, for Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) in London, July 12–15, 2026. This announcement follows the recent FDA IND clearance for VY1706, which will allow for a clinical trial in adults with early Alzheimer's, with patient dosing anticipated in the second half of 2026. The poster will detail the IND-enabling GLP non-human primate study of VY1706, a BBB-crossing AAV gene therapy targeting tau.
Price to earnings forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
This page provides financial information for Voyager Therapeutics, Inc. (NASDAQ: VYGR), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data placeholder from TradingView, indicating where detailed financial metrics for the company would be displayed.
Enterprise value to EBIT forward of Voyager Therapeutics, Inc. – FWB:VT6
This article provides financial information for Voyager Therapeutics, Inc. (FWB:VT6), specifically focusing on its enterprise value to EBIT forward. The content appears to be a direct data point from a financial platform like TradingView, indicating a value for this metric during a closed market period.
Voyager to present Alzheimer’s gene therapy data at AAIC By Investing.com
Voyager Therapeutics Inc. (NASDAQ:VYGR) is set to present preclinical data for its Alzheimer’s gene therapy, VY1706, at the Alzheimer’s Association International Conference. The company recently received FDA clearance for its Investigational New Drug application and plans to start clinical trials in the second half of 2026. Preclinical studies indicate that VY1706 significantly reduced tau protein levels by up to 75% in non-human primates without adverse effects, suggesting potential for a one-time intravenous treatment for early Alzheimer's disease.
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s
Voyager Therapeutics announced that its investigational gene therapy, VY1706, for Alzheimer's disease will be featured in a late-breaking poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) in London. The company recently received FDA Investigational New Drug (IND) clearance for VY1706, enabling the initiation of a clinical trial in adults with early AD, with dosing expected to begin in the second half of 2026. VY1706 targets tau protein, reducing its levels in the brain, and has shown a favorable tolerability profile in preclinical studies.
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s
Voyager Therapeutics announced a late-breaking poster presentation at the Alzheimer's Association International Conference 2026, featuring their investigational gene therapy VY1706 for Alzheimer's disease. VY1706, which targets tau protein, recently received FDA IND clearance, allowing for a clinical trial in early AD patients, with dosing expected to begin in the second half of 2026. The therapy uses a vectorized siRNA delivered via a TRACER™ AAV capsid to reduce both intracellular and extracellular tau levels in the brain.
VYGR Forecast — Price Target — Prediction for 2027
This article provides a forecast for Voyager Therapeutics, Inc. (VYGR) stock, including analyst price targets and ratings. It details the stock's current price, historical performance, financial metrics like earnings and revenue, and upcoming earnings dates. The forecast section indicates a maximum estimated price of $25.00 and a minimum of $8.00 based on analyst opinions.
Voyager Therapeutics, Inc. Actuals & Estimates (NASDAQ:VYGR)
This article provides an overview of Voyager Therapeutics, Inc. (NASDAQ: VYGR) stock performance, financial actuals and estimates, and analyst forecasts. It details current stock price, volatility, market capitalization, earnings, and revenue, alongside historical highs and lows. The company's next earnings report is scheduled for July 30, 2026, and it currently does not pay dividends.
H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics (VYGR) with a $25.00 price target. This follows a previous Buy rating from TD Cowen. The company reported a Q1 revenue of $2.59 million and a net loss of $27.94 million, while corporate insider sentiment for the stock is negative due to recent share sales.
Voyager Therapeutics, Inc. Actuals & Estimates (MUN:VT6)
This article provides an overview of Voyager Therapeutics, Inc. (VT6), including its financial actuals and estimates, stock forecast, and historical price data. It details the company's past earnings and revenue performance, along with analyst predictions for future quarters. The report also addresses common questions about VT6's stock ticker, dividend policy, and employee count.
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Voyager Therapeutics Inc (VYGR), identifying its major shareholders and their respective proportions, such as Neurocrine Biosciences Inc, EcoR1 Capital, LLC, and Armistice Capital LLC. It also presents a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity, including changes in holdings. Additionally, it lists various ETFs that include VYGR in their portfolios.
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses the revenue breakdown of Voyager Therapeutics Inc (VYGR), focusing on business segments, regional revenue, and profit contribution. However, it explicitly states that relevant data for these categories have not been disclosed by the company yet. Despite the lack of specific financial details, the article aims to provide an overview of the company's financial structure.
Voyager Therapeutics, Inc. Stock 12‑Month Price Target Raised to $15.38, Implies 325% Upside
Voyager Therapeutics, Inc. (VYGR) has had its average 12-month price target raised from $14.89 to $15.38 by 8 analysts, suggesting a 325% potential upside from its June 17 closing price. The consensus rating among 10 covering analysts remains a "Buy," with no "Hold" or "Sell" recommendations.
Voyager Therapeutics Inc (VYGR) Earnings Forecast: Future EPS & Revenue Growth Estimates
Voyager Therapeutics Inc (VYGR) has an earnings forecast score of 9.09, placing it in the top 10 within the Biotechnology & Medical Research industry. Analysts have assigned a strong buy rating with an average price target of $12.00, suggesting a significant upside. The company's expected revenue for the next quarter is $6.04 million, and its EPS for the previous quarter met expectations at -$0.47, with -$0.49 projected for the upcoming quarter.
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics, Inc. announced that its CEO, Alfred W. Sandrock, Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The webcast will be available on the Investors section of Voyager's website starting at 7:00 a.m. ET on June 15, 2026. Voyager focuses on leveraging genetics to treat neurological diseases, with programs for Alzheimer's, Friedreich's ataxia, Parkinson's, ALS, and other central nervous system diseases.
Voyager Therapeutics (VYGR) director awarded 30,000 stock options at $3.43
Voyager Therapeutics director George A. Scangos was granted 30,000 stock options as director compensation, with an exercise price of $3.43 per share and an expiration date of June 9, 2036. The options vest upon the earlier of one year from the grant date or the next annual stockholders' meeting, subject to his continued service. This transaction is a compensation-related grant and not an open-market purchase or sale.
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics, Inc. announced that CEO Alfred W. Sandrock, Jr. will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The webcast will be available on Voyager's investor relations website starting June 15, 2026, at 7:00 a.m. ET. Voyager is a biotechnology company focused on using genetics to treat neurological diseases, including Alzheimer's, Friedreich's ataxia, and Parkinson's.
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics, Inc. announced that its CEO, Alfred W. Sandrock, Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The webcast will be available on-demand from the investors section of Voyager’s website starting June 15, 2026, at 7:00 a.m. ET. Voyager is a biotechnology company focused on using genetics to treat neurological diseases, with a pipeline including programs for Alzheimer’s, Friedreich’s ataxia, and Parkinson’s.
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics, Inc. announced that its Chief Executive Officer, Alfred W. Sandrock, Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the chat will be available on Voyager’s investor relations website starting June 15, 2026, at 7:00 a.m. ET. Voyager is a biotechnology company focused on leveraging genetics to treat neurological diseases, with a pipeline addressing conditions like Alzheimer’s, Parkinson’s, and ALS.
Voyager Therapeutics (VYGR) grants director Glenn Pierce 30,000 stock options
Voyager Therapeutics (VYGR) director Glenn Pierce was granted 30,000 stock options with an exercise price of $3.43 per share, expiring on June 9, 2036. This grant, made under the 2025 Stock Incentive Plan, vests on the earlier of one year from the grant date or the next annual stockholders’ meeting, contingent on his continued board service. The transaction is classified as routine equity compensation for a director, not an open-market purchase or sale.
Voyager Therapeutics (VYGR) grants director 30,000 stock options at $3.43
Voyager Therapeutics, Inc. (VYGR) director Catherine J. Mackey was granted 30,000 stock options with an exercise price of $3.43 per share, expiring on June 9, 2036. The options vest upon the earlier of one year from the grant date or the next annual stockholder meeting, provided she continues her service as a director, as per the company's 2025 Stock Incentive Plan. This transaction highlights the company's director compensation policy and increases Ms. Mackey's total derivative holdings from this grant to 30,000 shares.
Voyager Therapeutics (VYGR) director awarded 30,000 stock options at $3.43
Voyager Therapeutics director Jude Onyia was granted 30,000 stock options with an exercise price of $3.43 per share, expiring on June 9, 2036. These options were issued under the company’s 2025 Stock Incentive Plan as part of its director compensation policy. The underlying shares vest upon the earlier of one year from the grant date or the next annual stockholder meeting, contingent on his continued board service.
Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading
Voyager Therapeutics (VYGR) director Steven Hyman was granted 30,000 stock options at an exercise price of $3.43 per share. This award was made under the company's 2025 Stock Incentive Plan as part of its director compensation. The options vest upon the earlier of one year from the grant date or the next annual meeting of stockholders, contingent on Hyman's continued service.
Voyager Therapeutics (VYGR) director granted 30,000 stock options at $3.43
Voyager Therapeutics director James A. Geraghty was granted 30,000 stock options at an exercise price of $3.43 per share, expiring in 2036. The options vest upon the earlier of one year from the grant date or the next annual stockholders' meeting, provided he continues his service as director. This award was issued under the company's 2025 Stock Incentive Plan.
[8-K] Voyager Therapeutics, Inc. Reports Material Event
Voyager Therapeutics, Inc. reported that its stockholders approved an amendment to its charter at the 2026 Annual Meeting. This amendment significantly increases the authorized capital stock from 125,000,000 to 245,000,000 shares and authorized common stock from 120,000,000 to 240,000,000 shares, becoming effective on June 9, 2026. This move provides the company with greater flexibility for future equity-based actions without immediate dilution to current shareholders.
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
Voyager Therapeutics has received FDA IND clearance for VY1706, an investigational gene therapy for Alzheimer's disease targeting tau protein. This clearance allows for the initiation of a clinical trial in adults with early AD, with dosing anticipated in the second half of 2026. Preclinical data showed VY1706 can reduce tau protein levels in key brain regions by up to 75% following a single intravenous dose, leveraging Voyager's TRACER™ AAV capsid platform.
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
Voyager Therapeutics has received FDA IND clearance for VY1706, an investigational gene therapy aimed at reducing tau production in the brain for early Alzheimer's disease. This marks the first tau-targeted gene therapy to receive such clearance, with clinical trials expected to begin in H2 2026. The therapy uses a vectorized siRNA delivered via an IV-administered AAV capsid to decrease both intracellular and extracellular tau levels, showing promising preclinical results in reducing tau protein by up to 75% in relevant brain regions.
Guggenheim Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $22
Guggenheim has reiterated its Buy rating on Voyager Therapeutics (VYGR.US) and maintained its target price at $22. This suggests continued confidence in the company's prospects and valuation.
Voyager gets FDA clearance for Alzheimer’s gene therapy trial By Investing.com
Voyager Therapeutics Inc. has received FDA clearance for its Investigational New Drug application for VY1706, an experimental gene therapy targeting tau protein for Alzheimer’s disease. The company plans to start a multi-site, open-label, dose-escalation trial in the second half of 2026, marking the first IND clearance for a tau-targeted gene therapy. This positive development has been met with optimism from analysts and follows promising preclinical data, significantly boosting investor confidence.
Voyager Therapeutics receives FDA clearance to begin Alzheimer’s gene therapy trial
Voyager Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for VY1706, a gene therapy targeting tau protein in Alzheimer's disease. The company plans to initiate a multi-site, open-label, dose-escalation clinical trial in the second half of 2026, administering a single intravenous dose to adults with early-stage Alzheimer's and tau pathology. The trial will evaluate safety, tolerability, and VY1706's effect on tau biology, with positive toxicology data already reported from non-human primate studies.
Voyager gets FDA clearance for Alzheimer’s gene therapy trial By Investing.com
Voyager Therapeutics Inc. received FDA clearance for its Investigational New Drug application for VY1706, an experimental gene therapy targeting tau protein for Alzheimer’s disease. The company plans to initiate a multi-site, open-label, dose-escalation trial in the second half of 2026, marking the first IND clearance for a tau-targeted gene therapy. Preclinical studies showed significant reductions in tau protein, and analysts remain optimistic about the company's prospects.
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
Voyager Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for VY1706, a gene therapy targeting tau for Alzheimer's disease. Dosing of adults with early AD in a clinical trial is expected to begin in the second half of 2026. Preclinical studies of VY1706 have shown a compelling pharmacology and safety profile, demonstrating significant reduction of tau protein in key brain regions.
Voyager Therapeutics receives FDA clearance to begin Alzheimer’s gene therapy trial
Voyager Therapeutics has received FDA clearance for its Investigational New Drug application for VY1706, a gene therapy targeting tau protein in Alzheimer's disease. The company plans to initiate a multi-site, open-label, dose-escalation clinical trial in the second half of 2026 to evaluate the safety, tolerability, and effect of VY1706 on tau biology in early-stage Alzheimer's patients. This development follows positive toxicology data in non-human primates and reinforces analyst confidence, with H.C. Wainwright and Truist Securities reiterating Buy ratings.
FDA clears Voyager Therapeutics (VYGR) IND for Alzheimer’s gene therapy VY1706
Voyager Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for VY1706, a tau silencing gene therapy for Alzheimer's disease. This clearance enables the company to initiate a multi-site, open-label, dose-escalation clinical trial in the second half of 2026, enrolling up to 18 patients with early Alzheimer's. The study will evaluate the safety, tolerability, and effect of VY1706 on tau biology.
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
Voyager Therapeutics, Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for VY1706, a gene therapy targeting tau for Alzheimer’s disease. Dosing of adults with early AD in a clinical trial is expected to begin in the second half of 2026. The preclinical program for VY1706 demonstrated a compelling pharmacology and safety profile, with the therapy designed to durably reduce tau protein levels in key brain regions following a single IV administration.
One-time gene therapy to lower Alzheimer’s tau cleared for first human trial
Voyager Therapeutics (Nasdaq: VYGR) has received FDA IND clearance for VY1706, an intravenous-delivered gene therapy targeting tau in early Alzheimer’s disease. This clearance allows for the initiation of a multi-site, open-label, dose-escalation clinical trial in up to 18 patients, with dosing expected to begin in the second half of 2026. Preclinical data demonstrated significant reductions in tau protein and a favorable safety profile, positioning VY1706 as a potential next-generation treatment for Alzheimer's.
Voyager Therapeutics Announces Fda Clearance of Investigational New Drug Application for Vy1706 for Alzheimer's Disease
Voyager Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for VY1706, a tau silencing gene therapy for Alzheimer's disease. The company plans to start a multi-site, open-label, dose-escalation clinical trial in the second half of 2026, administering VY1706 as a one-time intravenous dose to adult participants with early AD and confirmed tau pathology. The trial will evaluate safety and tolerability, as well as the therapy's effect on tau biology through cerebrospinal fluid biomarkers and PET imaging.
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
Voyager Therapeutics has received FDA IND clearance for VY1706, an investigational gene therapy for Alzheimer's disease targeting tau protein. This clearance allows for the initiation of a clinical trial in adults with early AD, with dosing expected to begin in the second half of 2026. Preclinical data for VY1706 indicates a favorable safety profile and significant reductions in tau protein levels in key brain regions.
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained its target price at $25. This indicates a continued positive outlook from the firm regarding Voyager Therapeutics' stock performance.
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress
H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for Voyager Therapeutics (NASDAQ:VYGR) due to significant progress in its pipeline, particularly with the VY1706 program for Alzheimer's disease. The company completed a key toxicology study for VY1706, positioning it for an IND filing and potential first-in-human study in the second half of 2026. This positive outlook is supported by recent preclinical data and the company's strong financial position with more cash than debt.
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress
H.C. Wainwright maintained a Buy rating and a $25.00 price target for Voyager Therapeutics (NASDAQ: VYGR) due to significant pipeline advancements. The company completed a key toxicology study for its VY1706 program, an Alzheimer’s gene therapy, positioning it for an IND filing and first-in-human study in 2026. Analysts expect several value-inflection catalysts in the latter half of 2026, including clinical progression of VY1706 and data from VY7523.
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs
Voyager Therapeutics Inc (VGYR) has seen a modest 30% rise in its stock over the past year, but analysts predict a potential 250% surge in the next 12 months due to advancements in its drug programs. The company recently presented positive preclinical data for its Alzheimer's disease gene therapy, VY1706, which reduced tau protein in non-human primates by up to 64% without adverse events. Voyager plans to seek FDA authorization for human clinical trials of VY1706 in Q2 2026 and expects efficacy data for its VY7523 anti-tau antibody program in the latter half of the year.
Voyager Therapeutics (VYGR) accounting officer reports initial share and option holdings
Voyager Therapeutics' Principal Accounting Officer, Amy Quinlan, has filed an initial statement of beneficial ownership (Form 3), disclosing direct holdings of 36,749 common shares and two stock option awards covering a total of 78,500 shares. These options, granted under the company's 2015 and 2025 stock plans, vest over four years, aligning her interests with shareholders. The filing also details the vesting schedules and exercise prices of these equity awards.
EcoR1 and Oleg Nodelman report 0 shares in Voyager (NASDAQ: VYGR) amendment
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman have each reported 0 shares and 0% beneficial ownership of Voyager Therapeutics, Inc. (NASDAQ: VYGR) common stock in a Schedule 13G/A amendment. This filing indicates that these entities and individuals disclaim membership in a group and beneficial ownership, except to the extent of pecuniary interest, and was signed on May 14, 2026. The amendment is characterized as an informational filing that does not suggest an active stake or control intent in Voyager.
Voyager Therapeutics (NASDAQ: VYGR) affiliate files to sell 9,406 shares
An affiliate of Voyager Therapeutics (NASDAQ: VYGR) has filed a Form 144 to sell 9,406 shares of common stock, with the proposed transaction dated May 15, 2026. This filing is related to an option granted on February 6, 2026, and notes 60,421,287 shares outstanding as of May 15, 2026. The document also discloses a previous sale of 4,668 shares on February 24, 2026, which generated $17,588.09 in proceeds.
